Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Yasushi IshigakiAlena StrizekToshihiko AranishiNobuhiro AraiTakeshi ImaokaZhihong CaiHiroshi MaegawaPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
The study shows real-world benefits of GLP-1 RA therapy for T2DM, including improvements in HbA1c, body weight, and blood lipid profile, and supports the high rates of long-term persistence previously reported with dulaglutide, the GLP-1 RA most commonly prescribed for T2DM in Japanese clinical practice.